Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz

PURPOSE: To treat malaria, HIV-infected patients normally receive artemether (80 mg twice daily) concurrently with antiretroviral therapy and drug-drug interactions can potentially occur. Artemether is a substrate of CYP3A4 and CYP2B6, antiretrovirals such as efavirenz induce these enzymes and have...

Descripción completa

Detalles Bibliográficos
Autores principales: Siccardi, Marco, Olagunju, Adeniyi, Seden, Kay, Ebrahimjee, Farid, Rannard, Steve, Back, David, Owen, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4230487/
https://www.ncbi.nlm.nih.gov/pubmed/25505649
http://dx.doi.org/10.1186/2193-9616-1-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4230487/
https://www.ncbi.nlm.nih.gov/pubmed/25505649
http://dx.doi.org/10.1186/2193-9616-1-4

Ejemplares similares